Evaluation of the Acute flaccid paralysis surveillance indicators in Zambia from 2015-2021: a retrospective analysis.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
12 11 2023
Historique:
received: 13 03 2023
accepted: 02 11 2023
medline: 13 11 2023
pubmed: 12 11 2023
entrez: 11 11 2023
Statut: epublish

Résumé

The resurgence of poliovirus infection in previously polio free regions and countries calls for renewed commitment to the global polio eradication efforts including strengthening of Acute Flaccid Paralysis (AFP) surveillance systems. Zambia is one of the countries substantially at risk for the importation of poliovirus infection from neighbouring countries including Malawi, Mozambique, and Democratic Republic of the Congo (DRC). This study describes a seven-year AFP surveillance, assesses the surveillance indicators, and highlights areas for improvement. We conducted retrospective analysis of the routinely collected AFP surveillance data from January 2015 to December 2022. The AFP surveillance indicators performance was assessed using the World Health Organisation's recommended minimum AFP surveillance indicators performance. Cumulatively, a total of 1715 AFP cases were reported over the study period. More than half, 891 (52%) of reported cases were aged < 5 years with 917 (53.5%) of males. More than half, 1186 (69.2%) had fever at onset, 718 (41.9%) had asymmetric paralysis and 1164 (67.9%) had their paralysis progressed within 3 days of onset. The non-polio AFP rate ranges from 3.4 to 6.4 per 100,000 children < 15 years old and stool adequacy ranging from 70.9% to 90.2% indicating sensitive surveillance with late detection of cases. The percentage of cases with early stool collection, timely transportation was above the World Health Organisation (WHO) minimum of 80% but with declining proportion of stools arriving in the laboratory in optimal condition. Completeness of 60-days follow-up evaluation was suboptimal ranging from 0.9% to 28.2%. The AFP surveillance system in Zambia is doing well. However, additional efforts are needed to improve early detection of cases; stool sample collection, transportation and monitoring to ensure arrival in good condition in the laboratory; and improve 60-days follow-up evaluation for evidenced-based classification of inadequate AFP cases and proper care.

Sections du résumé

BACKGROUND
The resurgence of poliovirus infection in previously polio free regions and countries calls for renewed commitment to the global polio eradication efforts including strengthening of Acute Flaccid Paralysis (AFP) surveillance systems. Zambia is one of the countries substantially at risk for the importation of poliovirus infection from neighbouring countries including Malawi, Mozambique, and Democratic Republic of the Congo (DRC). This study describes a seven-year AFP surveillance, assesses the surveillance indicators, and highlights areas for improvement.
METHODS
We conducted retrospective analysis of the routinely collected AFP surveillance data from January 2015 to December 2022. The AFP surveillance indicators performance was assessed using the World Health Organisation's recommended minimum AFP surveillance indicators performance.
RESULTS
Cumulatively, a total of 1715 AFP cases were reported over the study period. More than half, 891 (52%) of reported cases were aged < 5 years with 917 (53.5%) of males. More than half, 1186 (69.2%) had fever at onset, 718 (41.9%) had asymmetric paralysis and 1164 (67.9%) had their paralysis progressed within 3 days of onset. The non-polio AFP rate ranges from 3.4 to 6.4 per 100,000 children < 15 years old and stool adequacy ranging from 70.9% to 90.2% indicating sensitive surveillance with late detection of cases. The percentage of cases with early stool collection, timely transportation was above the World Health Organisation (WHO) minimum of 80% but with declining proportion of stools arriving in the laboratory in optimal condition. Completeness of 60-days follow-up evaluation was suboptimal ranging from 0.9% to 28.2%.
CONCLUSION
The AFP surveillance system in Zambia is doing well. However, additional efforts are needed to improve early detection of cases; stool sample collection, transportation and monitoring to ensure arrival in good condition in the laboratory; and improve 60-days follow-up evaluation for evidenced-based classification of inadequate AFP cases and proper care.

Identifiants

pubmed: 37951902
doi: 10.1186/s12889-023-17141-1
pii: 10.1186/s12889-023-17141-1
pmc: PMC10640734
doi:

Substances chimiques

alpha-Fetoproteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2227

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : CDC HHS
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Pan Afr Med J. 2020 Jun 08;36:71
pubmed: 32754298
Pan Afr Med J. 2016 Jun 22;24:154
pubmed: 27642491
J Infect Dis. 2014 Nov 1;210 Suppl 1:S85-90
pubmed: 25316880
Epidemiol Health. 2016 Jul 19;38:e2016030
pubmed: 27457060
Pan Afr Med J. 2021 Jun 24;39:147
pubmed: 34527163
BMC Infect Dis. 2014 Aug 20;14:448
pubmed: 25141887
J Med Virol. 2023 Jan;95(1):e28265
pubmed: 36316293
BMC Infect Dis. 2009 Sep 30;9:162
pubmed: 19788763
J Paediatr Child Health. 2006 Jun;42(6):370-6
pubmed: 16737480
JMIR Public Health Surveill. 2019 Sep 27;5(3):e14217
pubmed: 31573938
Int Health. 2017 May 1;9(3):156-163
pubmed: 28582560
Pan Afr Med J. 2017 Jun 09;27(Suppl 2):10
pubmed: 28890751
Vaccine X. 2020 Mar 21;4:100059
pubmed: 32215368
J Infect Dis. 2014 Nov 1;210 Suppl 1:S540-6
pubmed: 25316878
Pan Afr Med J. 2022 Jun 11;42(Suppl 1):11
pubmed: 36158927
BMC Public Health. 2021 Jun 15;21(1):1148
pubmed: 34130684
BMC Public Health. 2014 Jul 05;14:687
pubmed: 24996415
Pan Afr Med J. 2013 Mar 05;14:86
pubmed: 23646222

Auteurs

Barnabas Bessing (B)

World Health Organization Country Office, Lusaka, Zambia. benabala1@gmail.com.

Edward A Dagoe (EA)

United States Centers for Disease Control and Prevention, Atlanta, USA.

Deborah Tembo (D)

Zambia National Public Health Institute, Lusaka, Zambia.

Alice Mwangombe (A)

World Health Organization Country Office, Lusaka, Zambia.

Muzala K Kanyanga (MK)

Zambia National Public Health Institute, Lusaka, Zambia.

Fadinding Manneh (F)

World Health Organization Africa Regional Office, Congo Brazzaville, Republic of Congo.

Belem B Matapo (BB)

World Health Organization Country Office, Lusaka, Zambia.

Patricia M Bobo (PM)

Ministry of Health Headquarters, Lusaka, Zambia.

Musole Chipoya (M)

McKing Consulting Corporation, Lusaka, Zambia.

Victor A Eboh (VA)

Taskforce for Global Health, Decatur GA, USA.

Princess L Kayeye (PL)

Ministry of Health Headquarters, Lusaka, Zambia.

Penelope K Masumbu (PK)

World Health Organization Country Office, Lusaka, Zambia.

Chilweza Muzongwe (C)

Ministry of Health Headquarters, Lusaka, Zambia.

Nathan N Bakyaita (NN)

World Health Organization Country Office, Lusaka, Zambia.

Delayo Zomahoun (D)

United States Centers for Disease Control and Prevention, Atlanta, USA.
World Health Organization Headquarters, Geneva, Switzerland.

Jude N Tuma (JN)

United States Centers for Disease Control and Prevention, Atlanta, USA.
World Health Organization Headquarters, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH